Stoke Therapeutics price target raised to $22 from $14 at Needham

Needham analyst Joseph Stringer raised the firm’s price target on Stoke Therapeutics to $22 from $14 and keeps a Buy rating on the shares. The analyst cites the company’s “impressive data” from the STK-001 Dravet Syndrome program that fit the firm’s best-case scenario and exceeded investor expectations. The 2- and 3-dose 70mg data from more patients showed a robust and consistent seizure reduction, while the FDA has also cleared the 3-dose 70mg loading dose, the firm tells investors in a research note.